A method for treating or preventing nociceptive pain by administering an ethanol extract of Brazilian green propolis and compositions comprising this extract.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

The present disclosure relates to an antigen-binding molecule that specifically binds to nerve growth factor (NGF) and uses thereof.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

Provided herein are pharmaceutical compositions that comprise myrcene, optionally in admixture with cannabinoids and other terpenes, typically substantially free of THC and THCA, for targeting TRPV1 receptors. Also provided are methods of using the pharmaceutical compositions to desensitize TRPV1 receptors in order to treat pain, cardiovascular diseases such as cardiac hypertrophy, overactive bladder, and chronic cough.

The present invention relates to cannabidiol (CBD), prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the treatment or prevention of pain caused by an indoleamine 2,3-dioxygenase-1 (IDO1) related disease.

The present invention relates to cannabidiol (CBD), prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the treatment or prevention of pain caused by an indoleamine 2,3-dioxygenase-1 (IDO1) related disease.

Provided herein is a ternary complex that, owing to its formulation, improves the bioavailability of certain molecules inside the body which act as active agents and which, due to their structure, are not absorbed because their solubility in water is highly limited or because their ingestion via a route such as the gastric route is not advisable based on the degradation it causes in the molecule. Likewise, the present invention relates to a method for obtaining this complex, as well as a pharmaceutical composition including the same, which is effective for preventing viral infectious processes, in addition to treating and preventing chronic and degenerative diseases by means of the antioxidant, anti-inflammatory and regenerative capacity of one of its components, the polyphenolic compounds.

Provided herein is a ternary complex that, owing to its formulation, improves the bioavailability of certain molecules inside the body which act as active agents and which, due to their structure, are not absorbed because their solubility in water is highly limited or because their ingestion via a route such as the gastric route is not advisable based on the degradation it causes in the molecule. Likewise, the present invention relates to a method for obtaining this complex, as well as a pharmaceutical composition including the same, which is effective for preventing viral infectious processes, in addition to treating and preventing chronic and degenerative diseases by means of the antioxidant, anti-inflammatory and regenerative capacity of one of its components, the polyphenolic compounds.

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.